| Literature DB >> 32213899 |
Yasuyuki Sakata1, Chikako Yoshida2, Yuka Fujiki2, Yutaka Matsunaga1, Hirohiko Nakamura1, Takashi Shimizu1, Yasuhiro Takeda1, Tatsuro Amano2.
Abstract
Food ingestion has been shown to affect thermoregulation during exercise, while the impact of protein degradant consumption remains unclear. We investigated the effects of casein hydrolysate ingestion on thermoregulatory responses during exercise in the heat. In a randomized, placebo-controlled, double-blind, crossover trial, five men and five women consumed either 5 g of casein hydrolysate or placebo. Thirty minutes after ingestion, participants cycled at 60% VO2max until voluntary exhaustion wearing a hot-water (43 °C) circulation suit. Exercise time to exhaustion, body core temperature, forearm sweat rate, and forearm cutaneous vascular conductance did not differ different between the conditions. However, chest sweat rate and mean skin temperature increased upon casein hydrolysate ingestion compared with placebo during exercise. Increased chest sweat rate upon casein hydrolysate ingestion was associated with elevated sudomotor sensitivity to increasing body core temperature, but not the temperature threshold for initiating sweating. A positive correlation was found between chest sweat rate and plasma total amino acid concentration during exercise. These results suggest that casein hydrolysate ingestion enhances sweating heterogeneously by increasing peripheral sensitivity of the chest's sweating mechanism and elevating skin temperature during exercise in the heat. However, the physiological link between plasma amino acid concentration and sweat rate remains unclear.Entities:
Keywords: aerobic exercise; body temperature; casein hydrolysate; exhaustion; heat; sweat rate; thermoregulation
Mesh:
Substances:
Year: 2020 PMID: 32213899 PMCID: PMC7146450 DOI: 10.3390/nu12030867
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 5.717
Amino acid composition of casein hydrolysate.
|
| |||||
| Lys | 77 | Cys | 3 | Tyr | 37 |
| Thr | 50 | Ile | 52 | Trp | 2 |
| Val | 62 | Leu | 81 | His | 25 |
| Met | 27 | Phe | 35 | ||
|
| |||||
| Asp + Asn | 85 | Pro | 108 | Arg | 25 |
| Ser | 63 | Gly | 21 | ||
| Glu + Gln | 282 | Ala | 34 | ||
Figure 1Schematic timeline of the experimental protocols for the preliminary and main experiments. RPE, rating of perceived exhaustion.
Figure 2Plot showing the trend of plasma total amino acid (TAA) concentration as a function of time following casein hydrolysate (CH) or placebo (PL) ingestion (n = 9) in the preliminary test. Values are expressed as mean ± SD. *, P < 0.001.
Physiological and perceptual responses in the preliminary experiment.
|
| Baseline | Time after the Supplementation | Interaction | |||||
|---|---|---|---|---|---|---|---|---|
| 30 min | 60 min | 90 min | 120 min | |||||
| Heart rate(beats/min) | CH | 10 | 72.2 ± 8.0 | 72.0 ± 6.7 | 74.8 ± 6.6 | 74.5 ± 7.8 | 76.0 ± 7.2 | n.s. |
| PL | 71.2 ± 7.1 | 71.1 ± 7.5 | 73.0 ± 7.9 | 73.3 ± 8.0 | 74.5 ± 8.6 | |||
| Mean arterial blood pressure (mmHg) | CH | 10 | 87.1 ± 6.1 | 85.2 ± 5.5 | 85.3 ± 5.0 | 84.7 ± 6.3 | 85.1 ± 6.8 | n.s. |
| PL | 85.1 ± 6.8 | 85.2 ± 7.8 | 85.4 ± 7.2 | 86.7 ± 5.9 | 85.8 ± 6.1 | |||
| Body core temperature (°C) | CH | 10 | 36.31 ± 1.01 | 36.24 ± 0.87 | 36.40 ± 0.76 | 36.53 ± 0.65 | 36.61 ± 0.56 | n.s. |
| PL | 36.65 ± 0.43 | 36.52 ± 0.37 | 36.58 ± 0.34 | 36.64 ± 0.30 | 36.73 ± 0.28 | |||
| Mean skin temperature (°C) | CH | 8 | 31.66 ± 0.94 | 31.92 ± 0.87 | 32.02 ± 0.91 | 32.13 ± 0.87 | 32.26 ± 0.72 | n.s. |
| PL | 31.62 ± 0.72 | 31.90 ± 0.37 | 31.96 ± 0.42 | 31.91 ± 0.37 | 31.95 ± 0.48 | |||
| Mean body temperature (°C) | CH | 8 | 35.29 ± 0.89 | 35.31 ± 0.72 | 35.48 ± 0.64 | 35.61 ± 0.55 | 35.72 ± 0.45 | n.s. |
| PL | 35.62 ± 0.46 | 35.61 ± 0.36 | 35.68 ± 0.34 | 35.73 ± 0.30 | 35.81 ± 0.26 | |||
| Skin Blood Flow (AU) | CH | 9 | 0.102 ± 0.023 | 0.104 ± 0.026 | 0.101 ± 0.022 | 0.101 ± 0.030 | 0.114 ± 0.032 | n.s. |
| PL | 0.109 ± 0.031 | 0.101 ± 0.021 | 0.100 ± 0.020 | 0.102 ± 0.024 | 0.105 ± 0.026 | |||
| CVC (AU/mmHg) | CH | 9 | 0.0012 ± 0.0003 | 0.0012 ± 0.0003 | 0.0012 ± 0.0003 | 0.0012 ± 0.0003 | 0.0013 ± 0.0003 | n.s. |
| PL | 0.0013 ± 0.0004 | 0.0011 ± 0.0002 | 0.0012 ± 0.0002 | 0.0012 ± 0.0002 | 0.0013 ± 0.0003 | |||
| Thermal sensation (AU) | CH | 10 | 3.2 ± 0.6 | 3.0 ± 0.8 | 3.0 ± 0.8 | 3.3 ± 0.9 | 3.6 ± 0.5 | n.s. |
| PL | 3.2 ± 0.9 | 3.0 ± 1.1 | 3.2 ± 0.6 | 3.1 ± 0.9 | 3.1 ± 0.7 | |||
Values are expressed as mean ± SD. CH, casein hydrolysate; PL, placebo; CVC, cutaneous vascular conductance; n.s., not significant.
Figure 3Time to exhaustion in casein hydrolysate (CH) and placebo (PL) conditions during exercise in the main experiment (n = 10). Values are expressed as mean ± SD.
Figure 4Changes in (a) body core temperature (n = 9), (b) mean skin temperature (n = 8), (c) chest sweat rate (n = 9), and (d) forearm sweat rate (n = 10) following casein hydrolysate (CH) or placebo (PL) ingestions in the main experiment. Values are expressed as mean ± SD. *, P < 0.05.
Physiological and perceptual responses in the main experiment.
|
| Baseline | Time after the Supplementation (Duration of Exercise) | Interaction | |||||
|---|---|---|---|---|---|---|---|---|
| 15 min (−15 min) | 30 min (0 min) | 45 min (15 min) | 55 min (25 min) | |||||
| Heart rate (beats/min) | CH | 10 | 70.9 ± 9.3 | 69.0 ± 8.7 | 70.7 ± 10.0 | 139.3 ± 7.6 | 147.7 ± 10.4 | n.s. |
| PL | 69.3 ± 6.5 | 66.6 ± 5.3 | 69.2 ± 6.7 | 138.1 ± 8.3 | 149.0 ± 11.5 | |||
| Mean arterial blood pressure (mmHg) | CH | 7 | 79.6 ± 4.2 | 78.0 ± 6.8 | 76.3 ± 6.8 | 86.5 ± 5.9 | - | n.s. |
| PL | 78.3 ± 5.0 | 76.1 ± 4.6 | 76.5 ± 7.7 | 85.3 ± 7.2 | ||||
| Body core temperature (°C) | CH | 9 | 36.73 ± 0.76 | 36.50 ± 0.77 | 36.48 ± 0.68 | 36.72 ± 0.53 | 37.03 ± 0.40 | n.s. |
| PL | 36.48 ± 0.76 | 36.34 ± 0.73 | 36.33 ± 0.71 | 36.55 ± 0.61 | 36.87 ± 0.60 | |||
| Mean skin temperature (°C) | CH | 8 | 31.52 ± 0.71 | 31.81 ± 0.88 | 32.06 ± 0.65 | 34.20 ± 0.91 | 34.67 ± 0.84 | |
| PL | 31.82 ± 0.98 | 31.98 ± 0.84 | 32.03 ± 0.82 | 34.00 ± 0.80 | 34.45 ± 0.58 | |||
| Mean body temperature (°C) | CH | 7 | 35.58 ± 0.58 | 35.45 ± 0.56 | 35.49 ± 0.50 | 36.15 ± 0.45 | 36.52 ± 0.35 | n.s. |
| PL | 35.50 ± 0.75 | 35.45 ± 0.72 | 35.45 ± 0.69 | 36.02 ± 0.56 | 36.37 ± 0.51 | |||
| Skin blood flow (AU) | CH | 10 | 0.084 ± 0.028 | 0.079 ± 0.015 | 0.082 ± 0.021 | 0.482 ± 0.326 | 0.699 ± 0.421 | n.s. |
| PL | 0.109 ± 0.046 | 0.094 ± 0.032 | 0.107 ± 0.034 | 0.491 ± 0.197 | 0.764 ± 0.338 | |||
| CVC (AU/mmHg) | CH | 7 | 0.0011 ± 0.0004 | 0.0010 ± 0.0001 | 0.0010 ± 0.0003 | 0.0039 ± 0.0016 | - | n.s. |
| PL | 0.0011 ± 0.0003 | 0.0011 ± 0.0003 | 0.0012 ± 0.0002 | 0.0039 ± 0.0013 | ||||
| Plasma TAA (μM) | CH | 10 | 2604 ± 257 | - | 3507 ± 344* | - | - | |
| PL | 2686 ± 242 | 2649 ± 292 | ||||||
| Thermal sensation (AU) | CH | 10 | 3.2 ± 1.0 | - | 3.3 ± 1.4 | 6.6 ± 0.7 | - | n.s. |
| PL | 3.4 ± 0.7 | 3.6 ± 1.3 | 6.5 ± 0.5 | |||||
| RPE (AU) | CH | 10 | 8.6 ± 2.2 | - | 9.4 ± 2.8 | 15.0 ± 2.3 | - | n.s. |
| PL | 8.5 ± 2.2 | 9.8 ± 2.8 | 14.2 ± 1.5 | |||||
Values are expressed as mean ± SD. CH, casein hydrolysate; PL, placebo; CVC, cutaneous vascular conductance; TAA, total amino acids; RPE, rating of perceived exhaustion; n.s., not significant.
Body core temperature and mean body temperature thresholds and slopes for sweating in the main experiment.
| Threshold (°C) | Slope (mg/cm2/min/°C) | |||||
|---|---|---|---|---|---|---|
| Tco | ΔTco | Tb | ΔTb | Tco | Tb | |
| Chest sweat rate | ||||||
| CH | 35.94 ± 0.44 * | 0.31 ± 0.22 | 35.47 ± 0.44 | 0.69 ± 0.24 | 0.97 ± 0.38 * | 0.79 ± 0.40 |
| PL | 35.72 ± 0.46 | 0.23 ± 0.22 | 35.26 ± 0.40 | 0.56 ± 0.29 | 0.71 ± 0.25 | 0.61 ± 0.29 |
| Forearm sweat rate | ||||||
| CH | 35.99 ± 0.45 * | 0.36 ± 0.21 | 35.53 ± 0.45 | 0.75 ± 0.26 | 0.79 ± 0.61 | 0.60 ± 0.37 |
| PL | 35.77 ± 0.40 | 0.29 ± 0.28 | 35.30 ± 0.31 | 0.60 ± 0.40 | 0.62 ± 0.32 | 0.59 ± 0.31 |
Values are expressed as mean ± SD. CH, casein hydrolysate; PL, placebo; Tco, body core temperature; Tb, mean body temperature; * P < 0.05.
Figure 5Relationship between changes in sweat rate (Δsweat rate) and plasma total amino acid (ΔTAA) concentration at 60 min after casein hydrolysate (CH) or placebo (PL) ingestion in the main experiment. Relationships (a) between Δsweat rate on the chest and ΔTAA (n = 18), and (b) between Δsweat rate on the forearm and ΔTAA (n = 19).